PE20211417A1 - Analogos novedosos de glp-1 - Google Patents

Analogos novedosos de glp-1

Info

Publication number
PE20211417A1
PE20211417A1 PE2020001535A PE2020001535A PE20211417A1 PE 20211417 A1 PE20211417 A1 PE 20211417A1 PE 2020001535 A PE2020001535 A PE 2020001535A PE 2020001535 A PE2020001535 A PE 2020001535A PE 20211417 A1 PE20211417 A1 PE 20211417A1
Authority
PE
Peru
Prior art keywords
analogs
glp
refers
action
duration
Prior art date
Application number
PE2020001535A
Other languages
English (en)
Inventor
Rajamannar Thennati
Nishith Chaturvedi
Vinod Sampatrao Burade
Pradeep Dinesh Shahi
Muthukumaran Natarajan
Ravishankara Madavati Nagaraja
Rishit Mansukhlal Zalawadia
Kunal Pandya
Brijeshkumar Patel
Dhiren Rameshchandra Joshi
Krunal Harishbhai Soni
Abhishek Tiwari
Vipulkumar Shankarbhai Patel
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of PE20211417A1 publication Critical patent/PE20211417A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transmission And Conversion Of Sensor Element Output (AREA)

Abstract

Esta referido a analogos novedosos del peptido similar al glucagon-1 (GLP-1) (7-37) que tienen una secuencia de aminoacidos con Leu o Ile en el C-terminal. Los nuevos analogos son potentes agonistas de GLP-1 con efecto adverso reducido y duracion de la accion mejorada. Tambien se refiere a derivados acilados de los nuevos analogos que tienen una potencia y duracion de la accion mejoradas adicionalmente y son adecuados para la administracion oral. Los analogos de la solicitud pueden ser utiles en el tratamiento de la diabetes y la obesidad.
PE2020001535A 2018-04-05 2019-04-05 Analogos novedosos de glp-1 PE20211417A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201821013109 2018-04-05
IN201821040474 2018-10-26
IN201821040468 2018-10-26
PCT/IB2019/052835 WO2019193576A1 (en) 2018-04-05 2019-04-05 Novel glp-1 analogues

Publications (1)

Publication Number Publication Date
PE20211417A1 true PE20211417A1 (es) 2021-08-02

Family

ID=66589592

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001535A PE20211417A1 (es) 2018-04-05 2019-04-05 Analogos novedosos de glp-1

Country Status (28)

Country Link
US (5) US11447535B2 (es)
EP (3) EP3774862B1 (es)
JP (2) JP7250814B2 (es)
KR (1) KR20200141469A (es)
CN (2) CN112236444A (es)
AU (2) AU2019247936C1 (es)
BR (1) BR112020020419A2 (es)
CA (1) CA3095988A1 (es)
CL (1) CL2020002574A1 (es)
CO (1) CO2020012425A2 (es)
DK (1) DK3774862T3 (es)
EC (1) ECSP20070185A (es)
ES (1) ES2925678T3 (es)
HR (1) HRP20221054T1 (es)
HU (1) HUE060135T2 (es)
IL (1) IL277483A (es)
JO (1) JOP20200251A1 (es)
LT (1) LT3774862T (es)
MX (1) MX2020010505A (es)
PE (1) PE20211417A1 (es)
PH (1) PH12020551591A1 (es)
PL (1) PL3774862T3 (es)
PT (1) PT3774862T (es)
RS (1) RS63523B1 (es)
SG (1) SG11202009467YA (es)
SI (1) SI3774862T1 (es)
WO (1) WO2019193576A1 (es)
ZA (1) ZA202306729B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019247936C1 (en) * 2018-04-05 2023-06-15 Sun Pharmaceutical Industries Limited Novel GLP-1 analogues
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
AU2021361263A1 (en) * 2020-10-17 2023-02-16 Sun Pharmaceutical Industries Limited GLP-1/GIP dual agonists
CN114685646B (zh) * 2020-12-31 2023-04-07 厦门赛诺邦格生物科技股份有限公司 一种多肽侧链类似物的制备方法及其应用
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
CN116514952B (zh) * 2022-10-13 2024-02-02 江苏师范大学 一类glp-1类似物及其应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
AU2610599A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
HU229208B1 (en) 2000-06-16 2013-09-30 Lilly Co Eli Glucagon-like peptide-1 analogs
JP2004528014A (ja) 2000-12-07 2004-09-16 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１融合タンパク質
WO2003058203A2 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
CN100354306C (zh) 2002-10-11 2007-12-12 株式会社三和化学研究所 Glp－1衍生物及其经粘膜吸收的制剂
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
CA2525574C (en) 2003-05-15 2015-06-30 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
CN101128214A (zh) 2005-03-18 2008-02-20 诺和诺德公司 长效glp-1化合物
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
CA2621699A1 (en) 2005-09-08 2007-03-15 Trustees Of Tufts College Stabilized glp-1 analogs
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
ES2532116T3 (es) 2007-09-05 2015-03-24 Novo Nordisk A/S Péptidos derivados con A-B-C-D y sus usos terapéuticos
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
ES2625735T3 (es) 2009-12-16 2017-07-20 Novo Nordisk A/S Análogos y derivados de GLP-1
CA2797431C (en) 2010-04-27 2016-06-21 Zhejiang Beta Pharma Inc. Glucagon-like peptide-1 analogue and use thereof
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
US9006178B2 (en) 2010-11-09 2015-04-14 Novo Nordisk A/S Double-acylated GLP-1 derivatives with a linker
ES2612278T3 (es) 2011-04-12 2017-05-16 Novo Nordisk A/S Derivados de GLP-1 doble-acilados
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN107266558A (zh) 2011-09-06 2017-10-20 诺沃—诺迪斯克有限公司 Glp‑1衍生物
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
WO2013167454A1 (en) 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
US11274135B2 (en) 2012-05-08 2022-03-15 Novo Nordisk A/S Double-acylated GLP-1 derivatives
CA2875743A1 (en) 2012-06-14 2013-12-19 Sanofi Exendin-4 peptide analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
EP3010546B1 (en) 2013-06-20 2017-08-09 Novo Nordisk A/S Glp-1 derivatives and uses thereof
WO2014209886A1 (en) 2013-06-23 2014-12-31 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptid-1
AU2014286234A1 (en) 2013-07-04 2015-12-17 Novo Nordisk A/S Derivatives of GLP-1 like peptides, and uses thereof
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
ES2688708T3 (es) * 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
CN105849123A (zh) 2013-12-13 2016-08-10 免疫医疗有限公司 蛋白酶抗性肽
WO2016083499A1 (en) 2014-11-27 2016-06-02 Novo Nordisk A/S Glp-1 derivatives and uses thereof
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
US10111932B2 (en) 2015-08-26 2018-10-30 Syracuse University Coagonists of glucagon-like peptide 1 receptor and neuropeptide Y2 receptor
US10946074B2 (en) 2016-03-03 2021-03-16 Novo Nordisk A/S GLP-1 derivatives and uses thereof
BR112018072968A2 (pt) 2016-06-09 2019-02-19 Medimmune Limited peptídeos monolipidados resistentes às proteases
MA46780A (fr) 2016-11-07 2019-09-11 Novo Nordisk As Esters à dchbs actif de composés peg et leur utilisation
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
WO2018178796A1 (en) * 2017-03-27 2018-10-04 Sun Pharmaceutical Industries Limited Method for making kex1 protease sensitive polypeptides using yeast strain
CA3093221A1 (en) 2018-03-09 2019-09-12 Enzypep B.V. Chemo-enzymatic synthesis of liraglutide, semaglutide and glp-1
AU2019247936C1 (en) * 2018-04-05 2023-06-15 Sun Pharmaceutical Industries Limited Novel GLP-1 analogues

Also Published As

Publication number Publication date
ZA202306729B (en) 2024-03-27
US20220402992A1 (en) 2022-12-22
SG11202009467YA (en) 2020-10-29
BR112020020419A2 (pt) 2021-01-19
IL277483A (en) 2020-11-30
US20190309040A1 (en) 2019-10-10
EP4122954A1 (en) 2023-01-25
PH12020551591A1 (en) 2021-08-16
US11447535B2 (en) 2022-09-20
SI3774862T1 (sl) 2022-10-28
JP2021520346A (ja) 2021-08-19
AU2019247936B2 (en) 2023-03-02
WO2019193576A1 (en) 2019-10-10
US11866477B2 (en) 2024-01-09
EP3774862B1 (en) 2022-06-08
HUE060135T2 (hu) 2023-02-28
KR20200141469A (ko) 2020-12-18
PL3774862T3 (pl) 2022-10-03
DK3774862T3 (da) 2022-09-05
AU2019247936A1 (en) 2020-10-15
EP3774862A1 (en) 2021-02-17
CN112236444A (zh) 2021-01-15
JP2023078367A (ja) 2023-06-06
HRP20221054T1 (hr) 2022-11-11
CL2020002574A1 (es) 2021-06-04
AU2019247936C1 (en) 2023-06-15
AU2023203430A1 (en) 2023-06-29
EP4364751A2 (en) 2024-05-08
US11873328B2 (en) 2024-01-16
CA3095988A1 (en) 2019-10-10
ECSP20070185A (es) 2021-01-29
US20220402991A1 (en) 2022-12-22
US11242373B2 (en) 2022-02-08
US11485766B2 (en) 2022-11-01
US20200362007A1 (en) 2020-11-19
US20210206823A1 (en) 2021-07-08
JP7250814B2 (ja) 2023-04-03
MX2020010505A (es) 2021-01-15
PT3774862T (pt) 2022-09-05
EP4122954B1 (en) 2024-04-03
RS63523B1 (sr) 2022-09-30
ES2925678T3 (es) 2022-10-19
CN117964735A (zh) 2024-05-03
CO2020012425A2 (es) 2020-12-21
JOP20200251A1 (ar) 2020-10-04
LT3774862T (lt) 2022-09-12

Similar Documents

Publication Publication Date Title
PE20211417A1 (es) Analogos novedosos de glp-1
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
PE20220590A1 (es) Agonistas del receptor del peptido-1 similar al glucagon
PE20240215A1 (es) Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
CO2021000453A2 (es) Compuestos coagonistas de gip/glp1
CO6280539A2 (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabolicos y obesidad
PE20180158A1 (es) Coagonistas de los receptores de glucagon y de glp-1
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
AR109274A2 (es) Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
AR099975A1 (es) Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
PE20200606A1 (es) Composiciones solidas para administracion oral
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
PE20100255A1 (es) Co-agonistas del receptor de glucagon/glp-1
PE20171380A1 (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
CL2020002718A1 (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos.
AR094358A1 (es) Derivados de péptidos insulinotrópicos cuya carga n-terminal está modificada
EA202092017A1 (ru) Новые аналоги glp-1
BR112022023834A2 (pt) Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo
AR119324A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1